New drug duo aims to shrink bladder tumors before surgery
NCT ID NCT05394337
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 39 times
Summary
This early-phase trial tests whether combining two immune-boosting drugs, atezolizumab and tiragolumab, can help control bladder cancer when given before surgery to remove the bladder and tumor. It includes 10 adults with muscle-invasive bladder cancer who cannot take the standard chemotherapy drug cisplatin. The study is currently recruiting at M.D. Anderson Cancer Center.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUSCLE-INVASIVE UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Atezolizumab and tiragolumab (given by IV)
What this could lead to
If successful, this combination could offer a new treatment option for bladder cancer patients who cannot receive standard chemotherapy before surgery.
What could go wrong
This is a very small early-phase trial with only 10 participants, so results may not apply to everyone. The drugs may cause side effects or fail to control the cancer.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.